Advanced woundcare company Crawford Healthcare has expanded into New Zealand and boosted its Australian offering through a new collaboration.
The Knutsford-based firm today (November 28) announced a partnership with Australasian medical supplies distributor EBOS Healthcare that will give it access to public and private hospitals and communities across both countries.
Crawford’s entire woundcare range recently launched in New Zealand as part of the deal. Its halo Ag OxysaltTM products will be made available in Australia by mid-2018.
Crawford Healthcare’s director of strategy, Chris Lane, said: "In EBOS Healthcare we’ve found a partner that shares our vision for improving healthcare outcomes through innovative products that address today’s most pressing healthcare challenges and the associated costs.”
"Market entry into New Zealand and expansion in Australia caps off a great year for Crawford’s international strategy, following significant development of our overseas operations in the Middle East and winning FDA-clearance for the KerraCel Ag range in the USA.”
Chris continued: "Our advanced wound care dressings, developed by our in-house R&D team, will continue to serve an expanding global audience for years to come, with diabetes prevalence and ageing populations universally on the rise.”
Crawford said the partnership with EBOS will "significantly increase” its overseas revenues and raise its share of an international wound care market expected to worth $22bn (£16.5bn) by 2022.
EBOS Healthcare’s national sales manager, Andrew Pickering, commented: "Long term partnership opportunities are critical to prospering in the Australian healthcare market.
"Our joint venture with Crawford provides a great platform for success, combining our established multi-channel market presence with some of the world’s most advanced products in wound care, which will perfectly cater to a growing demand in ANZ.”
Last month, Crawford Healthcare reported double-digit revenue growth in its latest half-year results, with turnover leaping 19% to £14.9m.
Read more at bdaily.co.uk